Search results for "Dilator"

showing 10 items of 273 documents

Dolichomegaösophagus bei Achalasie

2004

HISTORY AND CLINICAL FINDINGS A 78-year-old woman suffered from achalasia since 63 years with a progressive decompensation over the last year. 53 years ago, treatment with the Stark Dilator and 24 years ago, pneumatic dilation had been carried out. Currently, the patient presented with dysphagia for liquid and solid food, with permanent retrosternal pain and regurgitation for every meal, leading to a weight loss of 10 kg. INVESTIGATIONS The barium esophagogram showed a marked dilation of the esophagus with retinated secretions and food. The cardia had a maximum width of 15 mm. On endoscopy, reflux esophagitis and an insufficient lower esophageal sphincter were evident. TREATMENT AND COURSE …

medicine.medical_specialtymedicine.diagnostic_testbusiness.industrydigestive oral and skin physiologyAchalasiaGeneral Medicinemedicine.diseaseDysphagiadigestive system diseasesSurgeryEndoscopymedicine.anatomical_structureWeight lossDilatorotorhinolaryngologic diseasesmedicineDecompensationReflux esophagitismedicine.symptomEsophagusbusinessDMW - Deutsche Medizinische Wochenschrift
researchProduct

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension deliver…

2018

COPD causes considerable health and economic burden worldwide, with incidence of the disease expected to continue to rise. Inhaled bronchodilators, such as long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs), are central to the maintenance treatment of patients with COPD. Clinical studies have demonstrated that combined LAMA + LABA therapies improve efficacy while retaining a safety profile similar to LAMA or LABA alone. This has led to the development of several LAMA/LABA fixed-dose combination (FDC) therapies, which provide patients with the convenience of two active compounds in a single inhaler. GFF MDI (Bevespi Aerosphere®) is an FDC of glycopyrrolate/formote…

medicine.medical_specialtymedicine.drug_classDrug CompoundingFixed-dose combinationMuscarinic AntagonistsPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineFormoterol FumarateBronchodilatorAdministration InhalationmedicineHumans030212 general & internal medicineIntensive care medicineAdrenergic beta-2 Receptor AgonistsGlycopyrrolateCOPDbiologybusiness.industryInhalerGeneral MedicineLamamedicine.diseasebiology.organism_classificationGlycopyrrolateMetered-dose inhalerBronchodilator AgentsDrug CombinationsTreatment Outcome030228 respiratory systemFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.

2018

OBJECTIVE To determine the current state of knowledge and provide evidence-based recommendations that could be valid for all specialists taking care of female pattern hair loss (FPHL), a common form of hair loss in women that is characterized by the reduction of hair density in the central area of the scalp, whereas the frontal hairline is generally well conserved. PARTICIPANTS An expert task force appointed by the Androgen Excess and PCOS Society, which included specialists from dermatology, endocrinology, and reproductive endocrinology. DESIGN Levels of evidence were assessed and graded from A to D. Peer-reviewed studies evaluating FPHL published through December 2017 were reviewed. Crite…

medicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismVasodilator AgentsClinical BiochemistryReproductive EndocrinologySpironolactoneAndrogen ExcessBiochemistry030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineEndocrinology5-alpha Reductase InhibitorsInternal medicinemedicineVitamin D and neurologyHumansLow-Level Light TherapyMineralocorticoid Receptor Antagonists030219 obstetrics & reproductive medicineScalpintegumentary systembusiness.industryPlatelet-Rich PlasmaBiochemistry (medical)HyperandrogenismAlopeciaAndrogen Antagonistsmedicine.diseaseAndrogenDermatologymedicine.anatomical_structureEndocrinologyHair lossMinoxidilScalpMinoxidilFemalebusinessHyperandrogenismmedicine.drugPolycystic Ovary SyndromeThe Journal of clinical endocrinology and metabolism
researchProduct

Steroid and vasoactive treatment for acute deafness after attempted hearing preservation acoustic neuroma surgery.

2004

<i>Objective:</i> To investigate whether intravenous steroid and vasoactive therapy in the acute postoperative period improves hearing outcome in patients who develop acute deafness after attempted hearing preservation surgery for acoustic neuroma (AN) through a retrosigmoid or a middle cranial fossa approach. <i>Study Design and Setting:</i> Retrospective controlled study in a tertiary care center. Thirty-six patients who had developed acute deafness after hearing preservation surgery for treatment of an AN were reviewed. Preoperative AAOHNS hearing class was A in 2, B in 2 and D in 32 patients. Twenty-seven patients were treated with prednisolone, hydroxyethyl star…

medicine.medical_specialtymedicine.drug_classHearing lossmedicine.medical_treatmentPrednisoloneVasodilator AgentsAnti-Inflammatory AgentsAcoustic neuromaDeafnessHydroxyethyl Starch DerivativesPostoperative ComplicationsAcoustic neuroma surgeryVasoactiveotorhinolaryngologic diseasesmedicineEvoked Potentials Auditory Brain StemHumansIn patientPentoxifyllineRetrospective StudiesSalvage TherapyHearing preservationChemotherapybusiness.industryNeuroma Acousticmedicine.diseaseSurgeryOtorhinolaryngologyAnesthesiaAcute DiseaseInjections IntravenousCorticosteroidDrug Therapy Combinationmedicine.symptombusinessORL; journal for oto-rhino-laryngology and its related specialties
researchProduct

Asthma-COPD overlap syndrome: recent advances in diagnostic criteria and prognostic significance.

2017

The term asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) has been proposed for individuals with features of both asthma and COPD. Several attempts have been done to define ACOS on the basis of medical history, symptoms, and functional findings. The main diagnostic criteria include airflow obstruction with a strong although incomplete reversibility to bronchodilation tests, a significant exposure to cigarette or biomass smoke, and a history of atopy or asthma. Additional diagnostic elements include eosinophilic airway and systemic inflammation, a good response to corticosteroid treatment, and a high concentration of exhaled nitric oxide. ACOS should be distinguish…

medicine.medical_specialtymedicine.drug_classPrognosiComorbidity030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineRisk FactorsInternal medicineBronchodilatorMedicineHumansMedical historyFunctional abilityAsthmaCOPDbusiness.industryRisk FactorMedicine (all)SmokingOverlap syndromeGeneral Medicinemedicine.diseasePrognosisComorbidityAsthmarespiratory tract diseases030228 respiratory systemExhaled nitric oxidebusinessHumanMinerva medica
researchProduct

Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simula…

2020

Omar S Usmani,1 Nicola Scichilone,2 Benjamin Mignot,3 Dennis Belmans,3 Cedric Van Holsbeke,3 Jan De Backer,3 Roberta De Maria,4 Erika Cuoghi,4 Eva Topole,4 George Georges4 1Airway Disease Section, National Heart and Lung Institute, Imperial College, London, UK; 2PROMISE Department of Medicine, University of Palermo, Palermo, Italy; 3FLUIDDA, Kontich, Belgium; 4Chiesi Farmaceutici, SpA, Parma, ItalyCorrespondence: George GeorgesChiesi USA Inc., 175 Regency Woods Place, Ste. 600, Cary, NC 27518, USATel +1 (919) 678 6611 x1536Email george.georges@chiesi.comIntroduction: There is a clear correlation between small airways dysfunction and poor clinical outcomes in patients with chronic obstructiv…

medicine.medical_specialtymedicine.drug_classRespiratory SystemUrologyInternational Journal of Chronic Obstructive Pulmonary DiseaseSettore MED/10 - Malattie Dell'Apparato RespiratoriotomographyDry powder inhalers Inhaled corticosteroid Long-acting beta2 agonist Long-acting muscarinic antagonist Metered dose inhalers Tomography X-ray computedinhaled corticosteroidFluticasone propionatePulmonary Disease Chronic Obstructivechemistry.chemical_compoundFormoterol FumarateBronchodilatorAdministration InhalationmedicineHumanslong-acting muscarinic antagonistComputer SimulationGlycopyrronium bromideRespiratory systemmetered dose inhalers1102 Cardiorespiratory Medicine and HaematologyOriginal Researchx-ray computedlcsh:RC705-779COPDScience & TechnologyInhalationbusiness.industrydry powder inhalersGeneral Medicinelcsh:Diseases of the respiratory systemrespiratory systemmedicine.diseaseBronchodilator AgentsDrug CombinationschemistryCorticosteroidVilanterolbusinessLife Sciences & Biomedicinelong-acting beta2 agonistmedicine.drugInternational Journal of COPD
researchProduct

Cigarette smoke-induced pulmonary endothelial dysfunction is partially suppressed by sildenafil.

2009

Abstract Cigarette smoke mediated oxidative stress and endothelial dysfunction are important processes in the pathogenesis of several lung disorders. In this study we evaluated the effect of PDE5 inhibition on pulmonary artery endothelial dysfunction induced by cigarette smoke in vitro . Human pulmonary artery endothelial cells (HPAEC) were incubated in the absence or presence of PDE5 inhibitor sildenafil (10 nM–1 μM), PKG agonist 8-Br-cGMP (1 mM), or the antioxidants dyphenyleneiodonium (DPI 1 μM) and N -acetylcysteine (NAC 1 mM) for 30 min. Then, cigarette smoke extract (CSE) was added for 24 h. CSE (2.5–10%)-induced ROS generation was suppressed by DPI, and partially reversed by sildenaf…

medicine.medical_specialtymedicine.drug_mechanism_of_actionSildenafilVasodilator AgentsPharmaceutical ScienceEnzyme-Linked Immunosorbent Assaymedicine.disease_causeNitric OxidePolymerase Chain ReactionPiperazinesSildenafil CitrateAcetylcysteinechemistry.chemical_compoundInternal medicineSmokeparasitic diseasesTobaccomedicineHumansSulfonesEndothelial dysfunctionPhosphodiesterase inhibitorLungCells CulturedDNA PrimersbiologyBase Sequencebusiness.industrymedicine.diseaseEndothelial stem cellEndocrinologychemistryEnzyme inhibitorPurinescardiovascular systembiology.proteinEndothelium VascularbusinessPhosphodiesterase 5 inhibitorOxidative stressmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Stud…

2020

Roland Buhl,1 Michael Dreher,2 Stephanie Korn,1 Christian Taube,3 Christian Stock,4 Christoph M Zehendner,5 Anke Kondla,5 Claus F Vogelmeier6 1Pulmonary Department, Johannes Gutenberg University Mainz, Mainz, Germany; 2Clinic of Cardiology, Pneumology, Angiology and Internal Medicine Intensive Care, University Hospital RWTH Aachen, Aachen, Germany; 3Clinic for Pneumonology, University Medicine Essen – Ruhrlandklinik, Essen, Germany; 4Biostatistics + Data Sciences Corp, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; 5HP Country Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; 6Department of Pneumology,…

medicine.medical_specialtytiotropium/olodaterolMedizinMuscarinic AntagonistsInternational Journal of Chronic Obstructive Pulmonary Disease03 medical and health scienceschemistry.chemical_compoundStudy ProtocolPulmonary Disease Chronic Obstructive0302 clinical medicineMaintenance therapySpiolto® Respimat®Internal medicineAdministration Inhalationmedicinemedia_common.cataloged_instanceCOPDHumansMulticenter Studies as Topic030212 general & internal medicineProspective StudiesEuropean unionTiotropium BromideAdrenergic beta-2 Receptor Agonistsmedia_commonCOPDbiologybusiness.industryInhalerOlodaterolGeneral MedicineLamamedicine.diseasebiology.organism_classificationLAMA/LABA/ICShumanitiesObstructive lung diseaseBenzoxazinesBronchodilator AgentsRegimen030228 respiratory systemchemistrytriple therapyDrug Therapy Combinationbusinesshormones hormone substitutes and hormone antagonistsInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Role of  1-Adrenoceptor Subtypes in Pupil Dilation Studied With Gene-Targeted Mice

2014

PURPOSE The α₁A-adrenoceptor (α₁A-AR) subtype was suggested to mediate contraction and trophic effects in the iris dilator muscle, and thus its pharmacological blockade may be involved in intraoperative floppy iris syndrome. We tested the hypothesis that the α₁A-AR mediates pupil dilation and trophic effects in the mouse iris. METHODS The α₁-AR subtype mRNA expression was quantified in iris tissue by real-time PCR. To assess the role of individual α₁-ARs for mediating pupil dilation, the α₁-AR agonist phenylephrine was topically applied to the ocular surface of mice deficient in one of the three α₁-AR subtypes (α₁A-AR(-/-), α₁B-AR(-/-), α₁D-AR(-/-), respectively) and wild-type controls. Cha…

medicine.medical_specialtyurogenital systemIntraoperative floppy iris syndromeAnatomyBiologymedicine.diseaseSensory SystemsPupilCellular and Molecular NeuroscienceOphthalmologyIris dilator muscleEndocrinologyAtrophyInternal medicinemedicinePupillary responseMydriasismedicine.symptomReceptorPhenylephrinemedicine.drugInvestigative Ophthalmology & Visual Science
researchProduct

Transdermal nitroglycerine treatment of shoulder tendinopathies in patients with spinal cord injuries.

2011

A clinical blind study was conducted to determine the efficacy of transdermal nitroglycerine treatment on the awareness of shoulder pain. This study aims to determine the effects of transdermal nitroglycerine on shoulder pain and on functional shoulder movement in patients with spinal cord injuries and shoulder tendinopathies. A second aim is to establish the side effects of the treatment. Hospital “La Fe” in Valencia, Spain. A total of 45 spinal cord injury patients, all of whom are wheelchair users with shoulder tendinopathy, were randomly divided into two groups: placebo (n=12) and experimental (n=33). The experimental group (EG) received transdermal treatment for 6 months in the form of…

musculoskeletal diseasesAdultMaleShouldersVasodilator AgentsTransdermal PatchPlaceboNitroglycerinDouble-Blind MethodShoulder PainmedicineHumansSpinal cord injuryFunctional movementSpinal Cord InjuriesTransdermalbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseSpinal cordPlacebo Effectmedicine.anatomical_structureTreatment OutcomeNeurologyAnesthesiaTendinopathyFemaleNeurology (clinical)TendinopathybusinessRange of motionhuman activitiesSpinal cord
researchProduct